(1) by late March, 1k+ patients received compassionate use of remdesivir. However, clinical report was very limited. It is understandable that front line doctors are very busy and it takes time to analyze data.
https://www.gilead.com/stories/articles/an-open-letter-from-our-chairman-and-ceo
March 28, 2020
(2) a report of compassionate use of remdesivir was published on NEJM. Good news: Lower mortality on ventilated patients compared to standard of care? Bad news: adverse events quite common
Compassionate Use of Remdesivir for Patients with Severe Covid-19
https://www.nejm.org/doi/full/10.1056/NEJMoa2007016
36 of 53 patients (68%) showed clinical improvement. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; Mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation.
A total of 32 patients (60%) reported adverse events during follow-up. The most common adverse events were increased hepatic enzymes, diarrhea, rash, renal impairment, and hypotension. A total of 12 patients (23%) had serious adverse events. The most common serious adverse events — multiple-organ-dysfunction syndrome, septic shock, acute kidney injury, and hypotension. Four patients (8%) discontinued remdesivir treatment prematurely.
(3) in early April, Gilead had supply of 140k treatment courses to distribute. TBH, it doesn't seem that it is widely used on severe patients in US if it is the game-changer. Maybe many doctors don't have access to it or are reluctant to use it without further data.
https://www.gilead.com/stories/articles/an-update-on-covid-19-from-our-chairman-and-ceo
April 04, 2020
(4) by late Apr, we can expect Gilead's severe patient trial result (open-label, over SOC, 400+ patients) and China's severe patient trial result (double-blinded, over placebo, 200+ patients)
https://www.gilead.com/stories/articles/an-open-letter-from-our-chairman-and-ceo-april-10
April 10, 2020
A summary of remdesivir trials with upcoming data readouts can be found
https://www.gilead.com/stories/-/media/gilead-blog/files/clinical-trials-infographic.pdf